CA2864173A1 - Combinaison d'antagonistes des recepteurs muscariniques et d'agonistes de l'adrenorecepteur beta -3 pour le traitement de la vessie hyperactive - Google Patents

Combinaison d'antagonistes des recepteurs muscariniques et d'agonistes de l'adrenorecepteur beta -3 pour le traitement de la vessie hyperactive Download PDF

Info

Publication number
CA2864173A1
CA2864173A1 CA2864173A CA2864173A CA2864173A1 CA 2864173 A1 CA2864173 A1 CA 2864173A1 CA 2864173 A CA2864173 A CA 2864173A CA 2864173 A CA2864173 A CA 2864173A CA 2864173 A1 CA2864173 A1 CA 2864173A1
Authority
CA
Canada
Prior art keywords
beta
overactive bladder
combination
muscarinic receptor
receptor antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2864173A
Other languages
English (en)
Inventor
Stephen Caltabiano
Eliot Ohlstein
Stewart Mccallum
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Velicept Therapeutics Inc
Original Assignee
AltheRx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AltheRx Inc filed Critical AltheRx Inc
Publication of CA2864173A1 publication Critical patent/CA2864173A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2864173A 2012-02-09 2013-02-08 Combinaison d'antagonistes des recepteurs muscariniques et d'agonistes de l'adrenorecepteur beta -3 pour le traitement de la vessie hyperactive Abandoned CA2864173A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261596893P 2012-02-09 2012-02-09
US61/596,893 2012-02-09
PCT/US2013/025285 WO2013119910A1 (fr) 2012-02-09 2013-02-08 Combinaison d'antagonistes des récepteurs muscariniques et d'agonistes de l'adrénorécepteur bêta -3 pour le traitement de la vessie hyperactive

Publications (1)

Publication Number Publication Date
CA2864173A1 true CA2864173A1 (fr) 2013-08-15

Family

ID=48948043

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2864173A Abandoned CA2864173A1 (fr) 2012-02-09 2013-02-08 Combinaison d'antagonistes des recepteurs muscariniques et d'agonistes de l'adrenorecepteur beta -3 pour le traitement de la vessie hyperactive

Country Status (13)

Country Link
EP (1) EP2811989A1 (fr)
JP (1) JP2015509931A (fr)
KR (1) KR20150020160A (fr)
CN (1) CN104684549A (fr)
AR (1) AR089957A1 (fr)
AU (1) AU2013216864A1 (fr)
CA (1) CA2864173A1 (fr)
HK (1) HK1204966A1 (fr)
IL (1) IL234033A0 (fr)
PH (1) PH12014501814A1 (fr)
SG (1) SG11201404776PA (fr)
TW (1) TW201338772A (fr)
WO (1) WO2013119910A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
US9522129B2 (en) 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
US9956194B2 (en) 2014-12-03 2018-05-01 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
CN108290824B (zh) 2015-10-23 2022-03-11 B3Ar治疗股份有限公司 索拉贝隆两性离子及其应用
KR101868438B1 (ko) 2017-04-13 2018-06-20 (주) 성운파마코피아 아미드 유도체의 제조방법

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL124473C (fr) 1960-07-26
US5677346A (en) 1995-01-31 1997-10-14 Sepracor, Inc. Treating urinary incontinence using (S)-desethyloxybutynin
US6123961A (en) 1996-09-25 2000-09-26 Bridge Pharma, Inc. Treating urinary incontinence with (R)-desethyloxybutynin and (R)-oxybutynin
GB9812709D0 (en) 1998-06-13 1998-08-12 Glaxo Group Ltd Chemical compounds
GB9929297D0 (en) 1999-12-11 2000-02-02 Glaxo Group Ltd Process
GB0102407D0 (en) 2001-01-31 2001-03-14 Glaxo Group Ltd Process
TW200800953A (en) * 2002-10-30 2008-01-01 Theravance Inc Intermediates for preparing substituted 4-amino-1-(pyridylmethyl) piperidine
EP1424079A1 (fr) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combinaison d'un agoniste du beta-3-récepteur et d'un inhibiteur de recaptage de sérotonine et/ou norépinéphrine
JP2010522751A (ja) * 2007-03-29 2010-07-08 メルク・シャープ・エンド・ドーム・コーポレイション 下部尿路症状の治療のための併用療法
PE20091825A1 (es) 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
EP2470021B1 (fr) 2009-08-27 2014-10-22 Merck Sharp & Dohme Corp. Nouveaux agonistes de récepteurs adrénergiques bêta 3 dérivés de pyrrolidine
JP5738871B2 (ja) * 2009-10-07 2015-06-24 メルク・シャープ・エンド・ドーム・コーポレイション β３アドレナリン作動性受容体アゴニスト及び抗ムスカリン剤を用いる併用療法

Also Published As

Publication number Publication date
HK1204966A1 (en) 2015-12-11
CN104684549A (zh) 2015-06-03
PH12014501814A1 (en) 2014-11-24
AU2013216864A1 (en) 2014-09-11
SG11201404776PA (en) 2014-09-26
EP2811989A1 (fr) 2014-12-17
TW201338772A (zh) 2013-10-01
KR20150020160A (ko) 2015-02-25
IL234033A0 (en) 2014-09-30
JP2015509931A (ja) 2015-04-02
WO2013119910A1 (fr) 2013-08-15
AR089957A1 (es) 2014-10-01

Similar Documents

Publication Publication Date Title
MX353105B (es) Combinaciones de agonistas del receptor beta-3-adrenergico y antagonistas del receptor muscarinico para tratar vejiga hiperactiva.
WO2015095423A3 (fr) Polythérapie comprenant des agonistes se liant à ox40 et des antagonistes se liant à l'axe pd-1
HRP20180915T1 (hr) Spojevi koji imaju aktivnost kao antagonist muskarinskog receptora i kao agonist beta2 adrenergijskog receptora
PH12014501814A1 (en) Combination of muscarinic receptor antagonists and beta-3 adrenoceptor agonists for treating overactive bladder
PL2928890T3 (pl) Związki wykazujące aktywność antagonisty receptorów muskarynowych i agonisty receptorów beta 2 adrenergicznych
SG195375A1 (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
KR20180085068A (ko) 무스카린 수용체 길항제 및 베타2 아드레날린 수용체 작용제 효능을 갖는 화합물
MX365242B (es) El uso del antagonista cxcr4: 1,1´-[1,4-fenileno-bis-(metileno)-bi s-1, 4, 8, 11-tetraazaciclotetradecano (plerixaflor) para el tratamiento del síndrome de whim.
IL253922B (en) Compounds with muscarinic receptor antagonist and adrenergic receptor agonist activity in cell 2
EP3463312A4 (fr) Schémas posologique pour agonistes de récepteurs adrénergiques bêta-3 et agents anti-muscariniques pour le traitement et la prévention de symptômes du bas appareil urinaire et d'une hyperactivité vésicale
IL242748B (en) Nmdar agonists for use in the treatment of autoimmune-induced glutamatergic receptor dysfunction
WO2011097336A3 (fr) Agonistes hautement sélectifs du récepteur 5-ht(2c) ayant une activité antagoniste au niveau du récepteur 5-ht(2b)
MX2017015047A (es) Compuestos que tienen actividad antagonista del receptor muscarinico y actividad agonista del receptor beta2 adrenergico.

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20180208